Depot medroxyprogesterone acetate contraception: Metabolic parameters and mood changes

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 41, Issue 5 SUPPL., 1996, Pages 401-406

  Westhoff, Carolyn ^a,b,c  

^a Presbyterian Hospital ^*  (United States)

^b Dept Clin Obstet Gynecol Pub H ^*  (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

bone mineral metabolism; contraception; depo medroxyprogesterone acetate; depression; DMPA; glucose tolerance; injectable contraception; lipids; weight changes

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE;

BONE MINERAL; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; GLUCOSE TOLERANCE; HORMONAL CONTRACEPTION; HUMAN; INSULIN BLOOD LEVEL; INTRAMUSCULAR DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; MOOD; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN;

BIOLOGY; BODY WEIGHT--CHANGES; CARBOHYDRATE METABOLIC EFFECTS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; CONTRACEPTIVE METHODS; DEPO-PROVERA--SIDE EFFECTS; DEPRESSION; DISEASES; FAMILY PLANNING; GLUCOSE METABOLISM EFFECTS; INJECTABLES; LIPID METABOLIC EFFECTS; LIPIDS; LITERATURE REVIEW; MEDROXYPROGESTERONE ACETATE--SIDE EFFECTS; MENTAL DISORDERS; METABOLIC EFFECTS; PHYSIOLOGY;

AFFECT; BONE AND BONES; CARBOHYDRATE METABOLISM; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; METABOLISM; WEIGHT GAIN;

EID: 0030008586     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Schwallie PC, Assenzo JR: Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-339
2. Fraser IS, Dennerstein GJ: Depo-Provera in an Australian metropolitan practice. Med J Aust 1994;160:553-556
3. Egan TM, Siegert RJ, Fairley NA: Use of hormonal contraceptives in an institutional setting: Reasons for use, consent and safety in women with psychiatric and intellectual disabilities. NZ Med J 1993;106:338-341
4. Cromer BA, Smith RD, Blair JA, et al: A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994;94:687-694
5. Westhoff C, Wieland D, Tiezzi L: Depression in users of depot medroxyprogesterone acetate. Contraception 1995;51:351-354
6. Lieu DFM, Ng CSA, Yong YM, et al: Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 1985;31:51-64
7. Deslypere JP, Thiery M, Vermeulen A: Effect of long-term hormonal contraception on plasma lipids. Contraception 1985;21:633-642
8. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction: A multicentered phase III comparative clinical trial of depot medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 1. Contraceptive effects. Contraception 1986;34:223-235
9. Oyelola O: Fasting plasma lipids, lipoproteins, and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Contraception 1993;47:445-454
10. Cundy T, Cornish J, Evans MC, et al: Recovery of bone density in women who stop using medroxyprogesterone acetate. Br Med J 1994;308:247-248
11. Mukherjea M, Mukherjee P, Biswas R: Long-term contraception with Depo-Provera: A clinical evaluation. Int J Fertil 1980;25:122-126
12. Moore LL, Valuck R, McDougall C, et al: A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995;52:215-220
13. Amatayakul K, Sivasomboon B, Thanangkul O: A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 1980;22:605-622
14. Downer S, Joel S, Allbright A, et al: A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993;67:1102-1105
15. Meyer WJ, Cole C, Emory E: Depo-Provera treatment for sex offending behavior: An evaluation of outcome. Bull Am Acad Psychiatr Law 1992;20:249-259
16. Cundy T, Evans M, Roberts H, et al: Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J 1991;303:13-16
17. Virutamasen P, Wangsuphachart S, Reinproayoon D, et al: Trabecular bone in long-term depot medroxyprogesterone acetate users. Asia Oceania J Obstet Gynaecol 1994;20:269-274
18. Naessen T, Olsson S-E, Gudmundson J: Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995;52:35-39
19. Mark S: Premenopausal bone loss and depot medroxyprogesterone acetate administration. Int J Gynecol Obstet 1994;47:269-272
20. Virutamasen P, Wongsrichanalai C, Tangkeo P, et al: Metabolic effects of depot medroxyprogesterone acetate in long-term users: A cross-sectional study. Int J Gynaecol Obstet 1986;24:291-296
21. Kamau RK, Maina FW, Kogondu C, et al: The effect of low-oestrogen combined pill, progestogen-only pill and medroxyprogesterone acetate on oral glucose tolerance test. E Afr Med J 1990;67:550-555
22. Amatayalkul K, Sivassomboon B, Singkamani R: Effects of medroxyprogesterone acetate on serum lipids, protein, glucose tolerance and liver function in Thai women. Contraception 1980;21:283-297
23. Kremer J, deBruijn HWA, Hindirks FR: Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot medroxyprogesterone acetate. Contraception 1980;22:359-367
24. Fajumi JO: Alterations in blood lipids and side effects induced by Depo-Provera in Nigerian women. Contraception 1983;27:161-175
25. Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al: Long-term effects of depot medroxyprogesterone acetate on lipoprotein metabolism. Contraception 1991;44:61-71
26. Fahmy K, Khairy M, Allam G, et al: Effect of depo medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991;44:431-444
27. Enk L, Landgren B-M, Lindberg U-B, et al: A prospective, one-year study on the effects of two long acting injectable contraceptives (depot medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992;24:85-89
28. World Health Organization: A multicentre comparative study of serum lipids and apolipoproteins in long-term use of DMPA and a control group of IUD users. Contraception 1993;47:177-191